- Home
- ZVSA vs REVB Comparison
ZVSA vs REVB Comparison
Compare ZVSA & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- REVB
- Stock Information
- Founded
- ZVSA 2014
- REVB 2020
- Country
- ZVSA United States
- REVB United States
- Employees
- ZVSA N/A
- REVB N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- ZVSA Health Care
- REVB Health Care
- Exchange
- ZVSA Nasdaq
- REVB Nasdaq
- Market Cap
- ZVSA 3.0M
- REVB 3.7M
- IPO Year
- ZVSA N/A
- REVB N/A
- Fundamental
- Price
- ZVSA $0.65
- REVB $0.81
- Analyst Decision
- ZVSA
- REVB
- Analyst Count
- ZVSA 0
- REVB 0
- Target Price
- ZVSA N/A
- REVB N/A
- AVG Volume (30 Days)
- ZVSA 1.4M
- REVB 2.9M
- Earning Date
- ZVSA 08-08-2025
- REVB 08-08-2025
- Dividend Yield
- ZVSA N/A
- REVB N/A
- EPS Growth
- ZVSA N/A
- REVB N/A
- EPS
- ZVSA N/A
- REVB N/A
- Revenue
- ZVSA N/A
- REVB N/A
- Revenue This Year
- ZVSA N/A
- REVB N/A
- Revenue Next Year
- ZVSA N/A
- REVB N/A
- P/E Ratio
- ZVSA N/A
- REVB N/A
- Revenue Growth
- ZVSA N/A
- REVB N/A
- 52 Week Low
- ZVSA $0.47
- REVB $0.70
- 52 Week High
- ZVSA $6.30
- REVB $56.00
- Technical
- Relative Strength Index (RSI)
- ZVSA 50.60
- REVB 24.19
- Support Level
- ZVSA $0.65
- REVB $0.71
- Resistance Level
- ZVSA $0.73
- REVB $0.98
- Average True Range (ATR)
- ZVSA 0.06
- REVB 0.06
- MACD
- ZVSA 0.00
- REVB 0.07
- Stochastic Oscillator
- ZVSA 36.04
- REVB 7.41
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).